# A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

> **NCT06007651** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 49 (actual)

## Conditions studied

- Dyslipidemias
- Non-Alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** LY3885125
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06007651
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-10
- **Primary completion:** 2025-02-12
- **Final completion:** 2025-02-12
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Participants were not dosed in Part B as per the protocol.
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06007651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06007651, "A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06007651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*